$1.84 Billion is the total value of BVF INC/IL's 62 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $97,914,000 | +1.9% | 2,053,991 | -10.2% | 5.33% | -9.9% |
| ACIU | Sell | AC IMMUNE SA | $47,916,000 | -37.1% | 9,818,758 | -13.3% | 2.61% | -44.4% |
| KURA | Sell | KURA ONCOLOGY INC | $45,626,000 | +0.8% | 1,489,112 | -46.4% | 2.48% | -10.9% |
| ARGX | Sell | ARGENX SEsponsored adr | $44,523,000 | -49.3% | 169,600 | -56.5% | 2.42% | -55.2% |
| REPL | Sell | REPLIMUNE GROUP INC | $38,946,000 | -32.3% | 1,691,834 | -26.9% | 2.12% | -40.2% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $38,738,000 | -12.2% | 3,499,346 | -0.5% | 2.11% | -22.4% |
| FBRX | Sell | FORTE BIOSCIENCES INC | $37,719,000 | +164.3% | 777,553 | -20.6% | 2.05% | +133.4% |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $34,878,000 | -58.4% | 735,055 | -48.3% | 1.90% | -63.3% |
| ANAB | Sell | ANAPTYSBIO INC | $18,104,000 | -37.4% | 1,227,405 | -5.2% | 0.99% | -44.7% |
| CALA | Sell | CALITHERA BIOSCIENCES INC | $15,820,000 | -57.7% | 4,585,638 | -35.3% | 0.86% | -62.7% |
| MEIP | Sell | MEI PHARMA INC | $12,730,000 | -25.4% | 4,080,162 | -1.2% | 0.69% | -34.1% |
| XFOR | Sell | X4 PHARMACEUTICALS INC | $5,368,000 | -43.0% | 792,892 | -21.6% | 0.29% | -49.7% |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -2,594,925 | -100.0% | -0.04% | – |
| SURF | Exit | SURFACE ONCOLOGY INC | $0 | – | -2,038,528 | -100.0% | -0.82% | – |
| BDTX | Exit | BLACK DIAMOND THERAPEUTICS INC | $0 | – | -378,788 | -100.0% | -0.98% | – |
| PRNB | Exit | PRINCIPIA BIOPHARMA INC | $0 | – | -1,484,674 | -100.0% | -5.47% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.